Blood: Venetok Unilitoximassi-benzomostin is used to treat recurring/refractic follicle lymphoma.

The CONTRALTO trial is an open-label Phase 2 study designed to evaluate the efficacy and safety of BCL-2 inhibitor Venetok (VEN) Vitoxy monoantigen (R), VEN combined benzodiamostin (B) and R, compared to BR alone to treat recurring/refractic follicle lymphoma.
patients without chemotherapy arms (Group A: VEN-R) received Venetok 800 mg/day and lytoxi monoantitor 375 mg/m2 (on the first day, 8 days, 15 days and 22 days of the first course of treatment ( C) ( D) and 4/6/8/10/12 on the first day of treatment.
patients with a queue containing chemotherapy were randomly assigned to VEN-BR (Group B: VEN 800 mg/day for 1 year, and 6 courses of BR (Benzamostin 90 mg/m2 D1), after safe contact with Venetok, 2 and lysoxi monoanti-resistant 375 mg/m2 D1)) or 6 courses of BR (Group C).
, 163 patients were included: 9 in safety tests, 52 in groups A, B and C, and 51 in groups A, B and C, respectively.
metabolic/remission rates in groups A, B and C were 17%, 75% and 69%, respectively.
only 61% of patients with the B treatment arm received a dose of 90% of the planned benzoestin, while 96% of patients with the C treatment arm received a dose of the plan.
blood toxicity in group B led to a reduction or suspension of the dose compared to Group C.
rate of adverse reactions in groups A, B and C was 51.9%, 93.9% and 60.0%, respectively.
, compared with Group C, the toxicity of VEN-BR increased and the dose of medication decreased, but the efficacy was similar.
Optimize dosages and programmes to maintain the dose strength of benzodiamostin and lyxident or improve the efficacy and tolerance of VEN combined phenylastin and lytoxides monoantigen, while VEN Unitoximatation data need to be further studied.
.